Letter by Noubiap and Kamtchum-Tatuene Regarding Article, “PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2): Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by de Ridder et al1 reporting the results of the PAIS 2 trial (Paracetamol [Acetaminophen] In Stroke 2) that assessed the effect of early treatment with high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of ≥36.5°C. Some of their findings and conclusions deserve further discussion.
The authors found no difference in the number of serious adverse events, including liver failure and infections, between patients treated with paracetamol (n=35 [26%]) and those treated with placebo (n=28 [24%]). Therefore, they concluded that treatment with high-dose paracetamol seemed to be safe as previously demonstrated in the PAIS trial (Paracetamol [Acetaminophen] In Stroke).2 However, although the use of paracetamol above …